Clinton Health Access Initiative

What Clinton Health Access Initiative does

Clinton Health Access Initiative (CHAI) is a nonprofit global health organization founded in 2002 by former U.S. President Bill Clinton, headquartered in Boston, Massachusetts, with approximately 1,001–5,000 employees operating in 35+ low- and middle-income countries. CHAI works directly with ministries of health and national health agencies to expand access to essential medicines and health commodities, strengthen health systems, and implement large-scale public health programs. Roughly 85% of CHAI staff are based in program countries, working as embedded technical and operational partners to governments.

CHAI's core operating model combines market shaping (demand aggregation and direct negotiation with pharmaceutical manufacturers to secure price reductions on essential medicines and health products), health systems strengthening (technical assistance, capacity building, and financing reform), and program implementation (operational support for national disease programs). The organization spans more than 20 health program areas including HIV/AIDS, malaria, tuberculosis, hepatitis, vaccines, maternal and newborn health, reproductive health, nutrition, cancer, cervical cancer, diabetes and hypertension, sickle cell disease, assistive technology, and medical oxygen. CHAI has negotiated landmark pricing agreements — including 60%+ reductions in first-line HIV drugs, 75% reductions in second-line HIV therapies, 75% reductions in pediatric HIV treatment, and sub-$1 dual HIV/syphilis diagnostics — generating over $1 billion in documented treatment cost savings on TLD alone.

CHAI is grant-funded, receiving revenue from governments, foundations, and multilateral organizations including the Bill & Melinda Gates Foundation, Unitaid, The Global Fund, Gavi, the Mastercard Foundation, and bilateral government donors. The organization has no commercial product pricing, no equity ownership, and no traditional revenue stream; it operates as a charitable nonprofit affiliated with the Clinton Foundation. CHAI's leadership team includes CEO Dr. Neil Buddy Shah, COO Joshua Chu, and CFO Jake Calhoun, and its Board is chaired by President Clinton with Vice Chairs Chelsea Clinton and Raymond G. Chambers.

Name

Clinton Health Access Initiative

Legal name

Clinton Health Access Initiative

Website

https://clintonhealthaccess.org

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Clinton Health Access Initiative (CHAI) is a nonprofit global health organization founded in 2002 that partners with 35+ low- and middle-income country governments to negotiate lower medicine prices, strengthen health systems, and implement programs spanning HIV/AIDS, malaria, maternal/child health, cancer, and other priorities.

Ownership category

akta.pro rank

Product category

Global Public Health Services

akta.pro primary industry

Monitoring, Evaluation, Research & Learning (MERL) for Global Health (BPADAIAO)

Keywords

• Global health access
• Market shaping pharmaceuticals
• Health systems strengthening
• Essential medicines pricing
• Public health technical assistance

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Philanthropic and Government Grants: CHAI is a nonprofit organization that receives funding from donors including governments, foundations, and multilateral organizations to support its mission of increasing access to health care in low- and middle-income countries.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CHAI is a nonprofit global health organization that partners with governments of low- and middle-income countries to increase access to essential medicines and quality health care. It provides technical assistance, market shaping, price negotiation with pharmaceutical manufacturers, and operational support to ministries of health across more than 35 countries, spanning HIV/AIDS, malaria, tuberculosis, maternal and child health, vaccines, cancer, and health systems strengthening programs.

Product overview

CHAI is a nonprofit global health organization, not a product company. It operates as a trusted strategic partner, operational partner, and market shaper working with governments to strengthen health systems and expand access to healthcare in low- and middle-income countries. CHAI's work spans multiple health areas including infectious diseases (HIV/AIDS, malaria, hepatitis, tuberculosis, COVID-19), women and children's health (maternal/newborn/reproductive health, vaccines, nutrition, diarrhea/pneumonia), non-communicable diseases (cancer, cervical cancer, diabetes/hypertension, sickle cell disease, assistive technology), and health systems strengthening (digital health, health financing, health workforce). Rather than offering a unified software product, CHAI provides technical assistance, market-shaping services, operational support, and program implementation assistance to partner governments across 35+ countries. The organization's value proposition lies in catalyzing equitable access to healthcare through four roles: Market Shaper (driving down prices of drugs and health commodities), Trusted Strategic Partner (supporting government health policy planning), Operational Partner (implementing health programs on the ground), and Ecosystem Catalyst (designing cross-sector solutions for transformational impact).

Differentiator

Problem solved

Functional benefit

Products and services

• HIV/AIDS Program Technical assistance and operational support to governments to expand access to antiretroviral therapy and HIV/AIDS treatment, including market shaping for affordable antiretrovirals and introduction of optimized regimens such as TLD.
• Malaria and Neglected Tropical Diseases Program Support to governments on malaria and neglected tropical disease funding, diagnosis, treatment, and supply chain, including price reductions for artemisinin-based combination therapies, injectable artesunate, and rapid diagnostic tests.
• Tuberculosis Program Program support to governments to expand access to TB diagnosis and treatment as part of CHAI's infectious diseases portfolio.
• Hepatitis Program Technical assistance to governments on hepatitis C treatment access, including negotiation of price reductions of 71-95% in seven countries.
• COVID-19 Response Program Support to countries on securing affordable supplies for COVID-19 treatment, including PPE, biomedical devices for oxygen therapy, and diagnostics.
• Oxygen Therapy Program Support to governments on medical oxygen access, including roadmap development, supply negotiations with manufacturers, and a regional oxygen manufacturing initiative in East Africa expected to triple oxygen production and reduce prices by up to 27%.
• Vaccines Program Government support to expand access to affordable vaccines, including price negotiation for rotavirus, pentavalent, and other vaccines.
• Maternal, Newborn, and Reproductive Health Program Programs to expand access to contraception, high-quality reproductive health care, and to reduce maternal and newborn mortality, including price reductions for long-acting reversible contraceptives.
• Nutrition Program Program support to governments on nutrition interventions for women and children.
• Diarrhea and Pneumonia Program Support to governments to scale up access to treatment for childhood diarrhea and pneumonia, including introduction of affordable zinc/ORS products.
• Cancer Program Program support to governments on cancer treatment access, including a 2017 agreement with the American Cancer Society, Pfizer, and Cipla to expand access to 16 essential cancer treatment medications in six African countries.
• Cervical Cancer Program Support to governments on cervical cancer screening and treatment, including partnership with governments to screen over 1 million women in 10 countries with more than 80% receiving appropriate treatment.
• Diabetes and Hypertension Program Program support to governments on prevention and management of diabetes and hypertension as part of CHAI's non-communicable disease portfolio.
• Sickle Cell Disease Program Program support to governments on sickle cell disease management and access to treatment.
• Assistive Technology Program Support to governments to increase access to assistive technology under the UK Aid-funded AT2030 program across 10 country governments.
• Digital Health Program Support to governments on digital health infrastructure and information systems as part of CHAI's health systems strengthening portfolio.
• Health Financing Program Support to governments on sustainable health financing, including work that expanded from HIV financing into broader sustainable health financing.
• Health Workforce Program Support to governments on health workforce education, training, and deployment, including establishing community health assistant programs in Rwanda and Zambia.
• Diagnostics Program Cross-cutting support to governments on access to diagnostics, including a 2018 breakthrough pricing agreement with Hologic for HIV, hepatitis, and cervical cancer diagnostic testing at $12 per patient sample.
• Market Shaping Program Cross-cutting market shaping program that aggregates demand and negotiates with pharmaceutical manufacturers to reduce prices of essential medicines and health products in low- and middle-income countries.
• Global Health Sciences Program Cross-cutting program providing evidence-based scientific support and analytics across CHAI's disease and health systems portfolios.
• Innovation Program (Maximum Impact Incubator) CHAI's Maximum Impact Incubator, led by the VP of Innovation, focused on strategic innovation and the development of new approaches and ventures to expand health impact.

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eleven partnerships are on record, tiered core and key.

• World Health Organization (WHO)coreStrategic or Co-development PartnerCHAI works with WHO on global health guidelines, norms, and standards, collaborating on disease elimination and health systems strengthening initiatives.
• UNICEFcoreStrategic or Co-development PartnerUNICEF is a key partner for CHAI in procuring and distributing essential medicines and health products to children and families in low- and middle-income countries.
• Gavi, the Vaccine AlliancecoreStrategic or Co-development PartnerCHAI collaborates with Gavi on vaccine access initiatives, supporting countries in introducing and scaling up life-saving vaccines.
• The Global FundcoreStrategic or Co-development PartnerThe Global Fund is a partnership organization that fights AIDS, tuberculosis, and malaria. CHAI works with The Global Fund to support countries in implementing and scaling programs financed by Global Fund grants.
• PfizerkeyStrategic or Co-development PartnerCHAI has worked with Pfizer on access to medicines initiatives, including negotiations for reduced pricing of essential medicines.
• ViatriskeyStrategic or Co-development PartnerCHAI collaborates with Viatris (formerly Mylan and Upjohn) on access to essential medicines, particularly in the areas of HIV/AIDS and other health products.
• CiplakeyStrategic or Co-development PartnerCHAI works with Cipla, a global pharmaceutical company, on manufacturing and supply chain initiatives to increase access to affordable medicines.
• Bristol Myers SquibbkeyStrategic or Co-development PartnerCHAI has partnered with Bristol Myers Squibb on access to medicines initiatives, particularly for treatments in low- and middle-income countries.
• RochekeyStrategic or Co-development PartnerCHAI has collaborated with Roche on cancer medicines access initiatives and negotiations for reduced pricing in low- and middle-income countries.
• Dr. Reddy's LaboratorieskeyStrategic or Co-development PartnerCHAI works with Dr. Reddy's Laboratories, an Indian pharmaceutical company, on generic medicine development and access initiatives.
• Hetero LabskeyStrategic or Co-development PartnerCHAI partners with Hetero Labs, a pharmaceutical company based in India, on manufacturing and supply chain initiatives for essential medicines.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Bill & Melinda Gates Foundation: The largest private global health funder, which both co-funds CHAI programs and operates its own global health delivery arm. Directly comparable as a global health institution with a major LMIC market-shaping agenda and overlapping disease portfolio (HIV, malaria, TB, vaccines, NCDs).

Direct peers

• Gavi, the Vaccine Alliance: Public-private partnership that procures and shapes vaccine markets for LMICs and is a core CHAI partner. Both organizations pool demand, negotiate with manufacturers, and co-fund country introductions—operating with a similar market-shaping playbook and overlapping ministry relationships.
• The Global Fund to Fight AIDS, Tuberculosis and Malaria: Largest multilateral financier of HIV, TB, and malaria programs in LMICs. CHAI is both a grant recipient and an in-country implementation partner; both organizations function as major funders and operational partners to ministries of health across the same country footprint.
• Unitaid: Global health agency that funds market-shaping interventions for HIV, TB, malaria, and women's and children's health. CHAI is one of Unitaid's most consistent implementation partners, jointly leading the price-reduction deals that defined both organizations.
• PATH: Global nonprofit that develops and delivers health technologies and market-shaping interventions across vaccines, drugs, and diagnostics in LMICs. Comparable to CHAI as a non-profit, multi-disease, country-embedded technical partner; partnered directly on the 2024 East Africa oxygen initiative.
• Partners In Health: US-based nonprofit providing direct healthcare delivery in resource-poor settings (Haiti, Rwanda, Sierra Leone, Liberia, Malawi). Comparable to CHAI in mission, LMIC country focus, and government-embedded model, though PIH leans more on service delivery while CHAI emphasizes market shaping and systems support.
• Doctors Without Borders / Médecins Sans Frontières (MSF): International medical humanitarian organization operating in conflict and epidemic settings across LMICs. Comparable as a major LMIC health-delivery NGO with overlapping geographies (Liberia, Sierra Leone, DRC, Nigeria) and overlapping program areas (HIV, TB, malaria, maternal health).
• Population Services International (PSI): Global health organization operating in 40+ countries with a focus on reproductive health, HIV, malaria, and non-communicable diseases. Comparable to CHAI in scale, LMIC country footprint, and donor-funded, government-partnered health programs.
• FHI 360: International development nonprofit with extensive global health, HIV, and health systems portfolios across Africa and Asia. Comparable to CHAI in funding sources, country footprint, and integrated public health program delivery model.

Emerging players

• FIND (Foundation for Innovative New Diagnostics): Global health non-profit focused on diagnostic access in LMICs. Directly comparable to CHAI's diagnostics and market-shaping work, and an actual CHAI alumni network—CHAI's VP of Child Health, Zachary Katz, was previously Chief Access Officer at FIND.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/clintonhealth
• YouTubeyoutube.com/user/ClintonHealth
• Facebookfacebook.com/clintonhealthaccess
• LinkedInlinkedin.com/company/clinton-health-access-initiative
• Instagraminstagram.com/chai_globalhealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles30 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinton Health Access Initiative